Missouri is currently home to 1896 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
NCT05104983
Recruiting
This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants. This study is supported by research funding from the Office of Orphan Products Division (OOPD) of the US Food and Drug Administration (FDA).
Gender:
ALL
Ages:
Between 1 day and 6 months
Trial Updated:
01/17/2025
Locations: Washington University -- St. Louis, Saint Louis, Missouri
Conditions: Tuberous Sclerosis Complex, Epilepsy
Register for Updates
Study of RP-6306 Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors
NCT04855656
Recruiting
The primary purpose of this study is to assess the safety and tolerability of RP-6306 alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
01/17/2025
Locations: Participating site #1011, St. Louis, Missouri
Conditions: Advanced Solid Tumor
Register for Updates
RESTORE Declined Livers Study
NCT04483102
Recruiting
This is a prospective, non-randomized, clinical trial of discarded liver transplants that have received normothermic machine perfusion (NMP), compared with standard cold preservation liver transplants. The discarded livers rejected by all other centers and meeting pre-NMP eligibility criteria will receive NMP using the OrganOx® metra device. The NMP-treated liver that meets the viability criteria will be transplanted to patients who are eligible and consented to the study. Liver transplant outco... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Liver Diseases, Surgery, Transplant; Failure, Liver
Register for Updates
Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)
NCT06673069
Recruiting
The primary purpose of this study is to evaluate the safety and tolerability of ION269 in adults with Down syndrome with evidence of brain amyloid positivity.
Gender:
ALL
Ages:
Between 35 years and 55 years
Trial Updated:
01/16/2025
Locations: Ionis Investigative Site, Saint Louis, Missouri
Conditions: Alzheimer Disease, Down Syndrome
Register for Updates
The Heart Outcomes in Pregnancy Expectations for Mom and Baby Study
NCT06517628
Recruiting
This is a prospective, observational study which is evaluating the obstetrical, neonatal, and cardiovascular outcomes of 1000 pregnant people with known heart disease to define how best to structure cardio-obstetrics care to optimize outcomes.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Saint Luke's Hospital of Kansas City, Kansas City, Missouri
Conditions: Pregnancy Complications, Cardiovascular
Register for Updates
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067
Recruiting
Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/16/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Advanced or Metastatic NRAS-mutant Melanoma
Register for Updates
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06130566
Recruiting
This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for SC injection compared with placebo in participant... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
01/16/2025
Locations: MediSearch Clinical Trials- Site Number : 8401140, Saint Joseph, Missouri
Conditions: Dermatitis Atopic
Register for Updates
Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
NCT05743595
Recruiting
This is a single institution, open-label, multi-arm, phase I study assessing the safety and immunogenicity of a personalized neoantigen-based personalized DNA vaccine combined with PD-1 blockade therapy in subjects with newly diagnosed, MGMT promoter unmethylated glioblastoma (GBM). Immune checkpoint blockade, specifically those targeting the PD-1/PD-L1 pathways, has shown efficacy in multiple solid and hematologic malignancies. Furthermore, as has been demonstrated in metastatic melanoma, comb... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Unmethylated Glioblastoma
Register for Updates
Myocardial Perfusion Imaging Galmydar Rest/Stress
NCT05625490
Recruiting
A single center, phase 0/1 clinical imaging study designed to assess the role of \[68Ga\]Galmydar PET/CT imaging in human subjects.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/16/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Coronary Artery Disease
Register for Updates
The Impact of Menthol Flavoring on Switching in Adult Menthol Smokers
NCT05555069
Recruiting
This study will compare the efficacy of menthol-flavored versus tobacco-flavored 4th generation nicotine salt-based pod-system e-cigarettes in facilitating a switch from combustible cigarettes to e-cigarettes in adult menthol smokers.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
01/16/2025
Locations: University of Kansas Medical Center, Kansas City, Missouri
Conditions: Smoking Reduction
Register for Updates
A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors
NCT04892017
Recruiting
This is a Phase 1/2, multicenter, open label, first in human (FIH) study of DCC-3116 as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Washington University Siteman Cancer Center, Saint Louis, Missouri
Conditions: Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
NCT04829604
Recruiting
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Research Site, Bolivar, Missouri
Conditions: HER2 Positive Metastatic Breast Cancer
Register for Updates